Effects of Abatacept in Patients With Early Rheumatoid Ar... | NCT02504268 | Trialant
NCT02504268
Sponsor
Bristol-Myers Squibb
Status
Completed
Last Update Posted
Jun 28, 2021Actual
Enrollment
994Actual
Phase
Phase 3
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Methotrexate
Abatacept Placebo
Methotrexate Placebo
Countries
United States
Argentina
Australia
Austria
Brazil
Canada
Chile
Colombia
Czechia
Finland
France
Germany
Hungary
Israel
Italy
Japan
Mexico
Monaco
Netherlands
Peru
Poland
Qatar
Romania
Russia
Singapore
South Africa
South Korea
Spain
Sweden
Taiwan
United Kingdom
Protocol Section
Identification Module
NCT ID
NCT02504268
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
IM101-550
Secondary IDs
ID
Type
Description
Link
2015-001275-50
EudraCT Number
Brief Title
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Official Title
A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive
Acronym
AVERT-2
Organization
Bristol-Myers SquibbINDUSTRY
Status Module
Record Verification Date
Jun 2021
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Sep 3, 2015Actual
Primary Completion Date
Jan 16, 2017Actual
Completion Date
Mar 19, 2020Actual
First Submitted Date
Jul 20, 2015
First Submission Date that Met QC Criteria
Jul 20, 2015
First Posted Date
Jul 21, 2015Estimated
Results Waived
Not provided
Results First Submitted Date
Jan 16, 2019
Results First Submitted that Met QC Criteria
Apr 4, 2019
Results First Posted Date
Apr 8, 2019Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Dec 6, 2017
Certification/Extension First Submitted that Passed QC Review
Dec 6, 2017
Certification/Extension First Posted Date
Dec 8, 2017Actual
Last Update Submitted Date
Jun 25, 2021
Last Update Posted Date
Jun 28, 2021Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Bristol-Myers SquibbINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
Detailed Description
Subcutaneous (SC)
Conditions Module
Conditions
Rheumatoid Arthritis
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 3
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
994Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Combination Therapy: Abatacept + Methotrexate
Experimental
Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
Drug: Abatacept
Drug: Methotrexate
Methotrexate treatment
Active Comparator
Methotrexate at least 15mg per week tablet or capsule orally
Drug: Methotrexate
Abatacept Placebo
Placebo Comparator
Placebo for Abatacept subcutaneous injection once per week
Other: Abatacept Placebo
Methotrexate Placebo
Placebo Comparator
Placebo to match Methotrexate capsule orally once per week
Other: Methotrexate Placebo
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Abatacept
Drug
Combination Therapy: Abatacept + Methotrexate
Methotrexate
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI <= 3.3.
Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI <= 3.3 indicates disease remission and SDAI >26 = high disease activity.
Week 24
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24
DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP <= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Rheumatoid arthritis (RA) diagnosis less than 6 months
Emery P, Fleischmann R, Wong R, Lozenski K, Tanaka Y, Bykerk V, Bingham CO 3rd, Huizinga TWJ, Citera G, Perera V, Murthy B, Maxwell KF, Passarell J, Hedrich WD, Williams D. Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study. J Rheumatol. 2025 May 1;52(5):426-435. doi: 10.3899/jrheum.2024-0498.
994 treated in the induction period (IP). 184 from IP randomized and treated in De-Escalation (DeE), 685 treated in the Open Label (OL) and 120 treated in the Open Label Extension (OLE) period. Participants in IP could move to the OL period after IP completion or through early IP escape. Participants from DeE could transfer to OL through early escape or to OLE after completing DeE.
Percentage of Participants in SDAI Remission at Week 52
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI <= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI <= 3.3 indicates disease remission and SDAI >26 = high disease activity.
Week 52
Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52
The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.
Week 52
Percentage of Participants in Boolean Remission at Week 52
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.
Week 52
Glendale
Arizona
85306
United States
Arizona Arthritis & Rheumatology Research PLLC
Mesa
Arizona
85210
United States
Arizona Arthritis & Rheumatology Research PLLC
Phoenix
Arizona
85032
United States
Arizona Arthritis & Rheumatology Research PLLC
Phoenix
Arizona
85037
United States
Arizona Arthritis & Rheumatology Research PLLC
Sun City
Arizona
85351
United States
CHI St. Vincent Medical Group Hot Springs
Hot Springs
Arkansas
71913
United States
Arkansas Primary Care Clinic
Little Rock
Arkansas
72204
United States
St. Joseph Heritage Medical Group
Fullerton
California
92835
United States
Healthcare Partners Medical Group
Huntington Beach
California
92646
United States
Valerius Medical Group and Research Center
Los Alamitos
California
90720
United States
Inland Rheumatology Clinical Trials Inc.
Upland
California
91786
United States
Joao Nascimento
Bridgeport
Connecticut
06606
United States
Rheumatology Associates Of Central Florida, P.A.
Orlando
Florida
32806
United States
Tampa Medical Group, Pa
Tampa
Florida
33614
United States
Coeur D'Alene Arthrit Clin
Coeur d'Alene
Idaho
83814
United States
Arthritis And Diabetes Clinic
Monroe
Louisiana
71203
United States
Klein And Associates, M.D., Pa
Hagerstown
Maryland
21740
United States
St. Paul Rheumatology, P.A.
Eagan
Minnesota
55121
United States
Arthritis Consultants
St Louis
Missouri
63141
United States
Physician Research Collaboration, Llc
Lincoln
Nebraska
68516
United States
Arthritis And Osteoporosis Associates, Pa
Freehold
New Jersey
07728
United States
Physicians Research Center, Llc
Toms River
New Jersey
08755
United States
Albuquerque Center For Rheumatology
Albuquerque
New Mexico
87102
United States
Albuquerque Clinical Trials
Albuquerque
New Mexico
87102
United States
Hospital For Special Surgery
New York
New York
10021-4892
United States
Local Institution
Hickory
North Carolina
28601
United States
Pmg Research Of Salisbury
Salisbury
North Carolina
28144
United States
Carolina Arthritis Associates
Wilmington
North Carolina
28401
United States
Pmg Research Of Wilmington Llc
Wilmington
North Carolina
28401
United States
Health Research Of Oklahoma
Oklahoma City
Oklahoma
73103
United States
Oklahoma Ctr For Arthritis Therapy And Research, Inc.
Tulsa
Oklahoma
74104
United States
Altoona Center For Clinical Research
Duncansville
Pennsylvania
16635
United States
The Arthritis Group
Philadelphia
Pennsylvania
19152
United States
Clinical Research Center Of Reading, Llp
Wyomissing
Pennsylvania
19610
United States
West Tennessee Research Institute
Jackson
Tennessee
38305
United States
Metroplex Clinical Research Center
Dallas
Texas
75231
United States
Houston Institute For Clinical Research
Houston
Texas
77074
United States
Arthritis Clinic Of Northern Virginia, P.C.
Arlington
Virginia
22205
United States
Spectrum Medical, Inc.
Danville
Virginia
24541
United States
Arthritis Northwest
Spokane
Washington
99204
United States
Rheumatic Disease Center
Glendale
Wisconsin
53217
United States
Organizacion Medica De Investigacion S.A. (Omi)
Capital Federal
Buenos Aires
1015
Argentina
Local Institution
Ciudad Autonoma Beunos Aires
Buenos Aires
1431
Argentina
Hospital General De Agudos J.M. Ramos Mejia
Ciudad Autonoma de Buenos Aire
Buenos Aires
1221
Argentina
Framingham Centro Medico
La Plata
Buenos Aires
1902
Argentina
Instituto de Asistencia Reumatologica Integral
San Fernando
Buenos Aires
1646
Argentina
Caici
Rosario
Santa Fe Province
2000
Argentina
Instituto De Rehabilitacion Psicofisica
Buenos Aires
1428
Argentina
Centro Consultora Integral de Salud SRL
Córdoba
5004
Argentina
Hospital Privado-Centro Medico De Cordoba S.A.
Córdoba
5016
Argentina
Centro De Investigaciones Reumatologicas
San Miguel de Tucumán
4000
Argentina
Centro Medico Privado De Reumatologia
San Miguel de Tucumán
4000
Argentina
Local Institution
Maroochydore
Queensland
4558
Australia
Local Institution
Southport
Queensland
4215
Australia
Local Institution
Hobart
Tasmania
7000
Australia
Local Institution
Camberwell
Victoria
3124
Australia
Local Institution
Coffs Harbour
2450
Australia
Rheuma Zentrum Favoriten
Vienna
1100
Austria
Local Institution
Juiz de Fora
Minas Gerais
36010-570
Brazil
Local Institution
Varginha
Minas Gerais
37006-710
Brazil
Local Institution
Curitiba
Paraná
80030-110
Brazil
Local Institution
Porto Alegre
Rio Grande do Sul
90480-000
Brazil
Local Institution
Santo André
São Paulo
09060-870
Brazil
Local Institution
São Paulo
01228-200
Brazil
Local Institution
São Paulo
04032-060
Brazil
Local Institution
São Paulo
04266-010
Brazil
Local Institution
Winnipeg
Manitoba
R3A 1M3
Canada
Local Institution
Montreal
Quebec
H2L 1S6
Canada
Centre De Recherche Musculo-Squelettique
Trois-Rivières
Quebec
G8Z 1Y2
Canada
Local Institution
Saskatchewan
Saskatchewan
S7K 0H6
Canada
Centro Medico de Reumatologia Limitada
Temuco
Araucania
4790928
Chile
Centro De Estudios Reumatologicos
Santiago
Santiago Metropolitan
7501126
Chile
Someal
Santiago
Santiago Metropolitan
7510586
Chile
Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S
Bogotá
Colombia
Fundacion Instituto de Reumatologia Fernando Chalem
Bogotá
Colombia
Clinica de Artritis Temprana
Cali
Colombia
Hospital Pablo Tobon Uribe
Medellín
MEDELLIN
Colombia
Oddeleni klinicke farmakologie
Plzen-Bory
305 99
Czechia
Revmatologicky ustav
Prague
128 50
Czechia
MEDICAL PLUS, s.r.o.
Uherské Hradiště
686 01
Czechia
PV Medical Services, s.r.o.
Zlín
760 01
Czechia
Local Institution
Hyvinkää
05800
Finland
Local Institution
Kuopio
70110
Finland
Local Institution
Lyon
69437
France
Local Institution
Orléans
45067
France
Local Institution
Poitiers
86021
France
Local Institution
Toulouse
31059
France
Rheumapraxis Dr. Kurthen
Aachen
52064
Germany
Charite Campus Mitte
Berlin
10117
Germany
Rheumatologische Schwerpunktpraxis Dr. Zinke
Berlin
13055
Germany
Immanuel Krankenhaus Berlin/Rheumaklinik Berlin Buch
Berlin
13125
Germany
Schlosspark-Klinik
Berlin
14059
Germany
Schwerpunktpraxis fuer Rheumatologie an den Kreiskliniken
Burghausen
84489
Germany
Klinikum Der Albrecht-Ludwigs-Universitat
Freiburg im Breisgau
79106
Germany
MVZ Rheuma
Hamburg
20095
Germany
Hamburger Rheuma Forschungszentrum
Hamburg
22391
Germany
Gemeinschaftspraxis Drs. von Hinueber u Demary
Hildesheim
31134
Germany
Rheumatologie In Wuermtal
Planegg
82152
Germany
Praxis Dr. Walter
Rendsburg
24768
Germany
Local Institution
Budapest
1027
Hungary
Belgyogy. Int. Reuma. DEOEC
Debrecen
4032
Hungary
Vaszary Kolos Hospital
Esztergom
2500
Hungary
Reumatologiai Osztaly Flor F.
Kistarcsa
2143
Hungary
Reumatologiai Osztaly MAV
Szolnok
5000
Hungary
Vital Medical Center
Veszprém
8200
Hungary
Local Institution
Haifa
31096
Israel
Local Institution
Petah Tikva
4941492
Israel
Local Institution
Ramat Gan
52621
Israel
Local Institution
Tel Litwinsky
52620
Israel
Local Institution
Zrifin
Israel
Ospedale Vittorio Emanuele
Catania
95123
Italy
Istituto Gaetano Pini
Milan
20122
Italy
Azienda Ospedaliera Luigi Sacco
Milan
20154
Italy
Local Institution
Pavia
27100
Italy
Local Institution
Roma
00168
Italy
Ospedale Borgo Roma
Verona
37134
Italy
Local Institution
Nagoya
Aichi-ken
4578511
Japan
Local Institution
Nagoya
Aichi-ken
4668560
Japan
Local Institution
Fukuoka
Fukuoka
8108563
Japan
Local Institution
Kitakyushu-shi
Fukuoka
8078556
Japan
Local Institution
Hiroshima
Hiroshima
7348551
Japan
Local Institution
Sapporo
Hokkaido
0608604
Japan
Local Institution
Sapporo
Hokkaido
0608648
Japan
Local Institution
Sapporo
Hokkaido
0630811
Japan
Local Institution
Kato-shi
Hyōgo
6731462
Japan
Local Institution
Hitachi-Naka
Ibaraki
3120057
Japan
Local Institution
Mito
Ibaraki
3100015
Japan
Local Institution
Kagoshima
Kagoshima-ken
8900063
Japan
Local Institution
Sagamihara-shi
Kanagawa
2520392
Japan
Local Institution
Isahaya-shi
Nagasaki
8548501
Japan
Local Institution
Sasebo-shi
Nagasaki
8571195
Japan
Local Institution
Tomigusuku-shi
Okinawa
9010224
Japan
Local Institution
Izumisano
Osaka
5988577
Japan
Local Institution
Kawachi-Nagano
Osaka
5868521
Japan
Local Institution
Iruma-gun
Saitama
3500495
Japan
Local Institution
Kawagoe-shi
Saitama
3508550
Japan
Local Institution
Sayama-shi
Saitama
3501305
Japan
Local Institution
Hamamatsu
Shizuoka
4308558
Japan
Local Institution
Chuo-ku
Tokyo
1048560
Japan
Local Institution
Itabashi-ku
Tokyo
1738610
Japan
Local Institution
Meguro-ku
Tokyo
1528902
Japan
Local Institution
Meguro-ku
Tokyo
1538515
Japan
Local Institution
Shinjuku-Ku
Tokyo
1608582
Japan
Local Institution
Mexico City
Distrito Fededral
11850
Mexico
Local Institution
Mexicali
Estado de Baja California
Mexico
Local Institution
León
Guanajuato
37000
Mexico
Local Institution
Guadalajara
Jalisco
44280
Mexico
Local Institution
Guadalajara
Jalisco
44600
Mexico
Local Institution
Guadalajara
Jalisco
Mexico
Local Institution
Guadalajara
Mexico
Local Institution
México D.F.
Mexico
Local Institution
San Luis Potosí City
78213
Mexico
Local Institution
Monaco
98012
Monaco
Local Institution
Leiden
2333 ZA
Netherlands
Local Institution
Lima
27
Peru
Acq Medic Sac
Lima
LIMA 11
Peru
Clinica El Golf
Lima
Lima 27
Peru
Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac
Lima
LIMA 33
Peru
Nszoz Unica Cr
Dąbrówka
62-069
Poland
Nzoz Mak Med
Nadarzyn
05-830
Poland
SANUS Szpital Specjalistyczny Sp. z o.o.
Stalowa Wola
37-450
Poland
Local Institution
Staszów
28-200
Poland
Slaski Szpital Reumatologiczno - Rehabilitacyjny
Ustroń
43-450
Poland
Instytut Reumatologii, I Klinika Reumatologii
Warsaw
02637
Poland
Centrum Medyczne AMED Sp. z o.o.
Warsaw
03-291
Poland
Local Institution
Doha
Qatar
Local Institution
Bucharest
011192
Romania
Local Institution
Bucharest
020983
Romania
Local Institution
Cluj-Napoca
400006
Romania
Local Institution
Moscow
119049
Russia
Local Institution
Saint Petersburg
191124
Russia
Local Institution
Saint Petersburg
197022
Russia
Local Institution
Yaroslavl
150003
Russia
Local Institution
Yekaterinburg
620102
Russia
Local Institution
Singapore
117549
Singapore
Local Institution
Singapore
169856
Singapore
Local Institution
Port Elizabeth
Eastern Cape
6045
South Africa
Local Institution
Soweto
Gauteng
2013
South Africa
Local Institution
Cape Town
Western Cape
7500
South Africa
Local Institution
Pinelands, Cape Town
Western Cape
7405
South Africa
Local Institution
Stellenbosch
Western Cape
7600
South Africa
Local Institution
Anyang-si
Gyeonggi-do
14068
South Korea
Local Institution
Seongnam-si
Gyeonggi-do
13620
South Korea
Local Institution
Seoul
04763
South Korea
Local Institution
A Coruña
15006
Spain
Local Institution
Barcelona
08036
Spain
Local Institution
Madrid
28006
Spain
Local Institution
Madrid
28046
Spain
Local Institution
Santiago Compostela
15702
Spain
Local Institution
Gothenburg
413 45
Sweden
Local Institution
Malmö
205 02
Sweden
Local Institution
Stockholm
171 76
Sweden
Local Institution
Uppsala
751 85
Sweden
Local Institution
Tainan
704
Taiwan
Local Institution
Taipei
100
Taiwan
Local Institution
Taipei
112
Taiwan
Local Institution
Taoyuan
333
Taiwan
Local Institution
Leeds
North Yorkshire
LS7 4SA
United Kingdom
Local Institution
Hull
HU3 2JZ
United Kingdom
Local Institution
Manchester
M13 9WL
United Kingdom
Derived
Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Citera G, Huang KG, Wu C, Connolly SE, Elbez Y, Wong R, Lozenski K, Fleischmann R. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. Arthritis Res Ther. 2023 Apr 22;25(1):67. doi: 10.1186/s13075-023-03038-2.
Emery P, Tanaka Y, Bykerk VP, Huizinga TWJ, Citera G, Bingham CO 3rd, Banerjee S, Soule BP, Nys M, Connolly SE, Lozenski KL, Zhuo J, Wong R, Huang KG, Fleischmann R. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. Rheumatol Ther. 2023 Jun;10(3):707-727. doi: 10.1007/s40744-022-00519-9. Epub 2023 Mar 3.
Wu C, Hu Y, Schafer P, Connolly SE, Wong R, Nielsen SH, Bay-Jensen AC, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TW, Fleischmann R, Liu J. Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD Open. 2022 Dec;8(2):e002683. doi: 10.1136/rmdopen-2022-002683.
Active abatacept SC (125 mg) weekly + methotrexate weekly
BG003
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG000451
BG001301
BG002242
BG003994
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
ParticipantsBG000451
ParticipantsBG001301
ParticipantsBG002242
ParticipantsBG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
ParticipantsBG000451
ParticipantsBG001301
ParticipantsBG002
Race/Ethnicity, Customized
Ethnicity data was collected for US Subjects only.
Number
Participants
Title
Denominators
Categories
WHITE
ParticipantsBG000451
ParticipantsBG001301
ParticipantsBG002
MODIFIED SHARP/VAN DER HEIJDE TOTAL SCORE (mTSS)
The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage.
Cohort 1 Analysis Population
Mean
Standard Deviation
Scores on a scale
Title
Denominators
Categories
ParticipantsBG000442
ParticipantsBG001292
ParticipantsBG002
Tender Joints - 28
number of painful joints from 28 joints
Cohort 1 Analysis Population
Mean
Standard Deviation
Joint Count
Title
Denominators
Categories
ParticipantsBG000448
ParticipantsBG001298
ParticipantsBG002
Swollen Joints - 28
number of swollen joints from 28 joints
Cohort 1 Analysis Population
Mean
Standard Deviation
Joint Count
Title
Denominators
Categories
ParticipantsBG000448
ParticipantsBG001298
ParticipantsBG002
Subject global assessment of disease activity
Subject's global assessment of disease activity by using a Visual Analog Scale (VAS). The scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]
Cohort 1 Analysis Population
Mean
Standard Deviation
mm
Title
Denominators
Categories
ParticipantsBG000450
ParticipantsBG001301
ParticipantsBG002
Physician global assessment of disease activity
physician's global assessment of disease activity using a Visual Analog Scale (VAS). The scale ranges from 0 to 100 mm, [0=no arthritis activity to 100 =extremely active arthritis]
Cohort 1 Analysis Population
Mean
Standard Deviation
mm
Title
Denominators
Categories
ParticipantsBG000446
ParticipantsBG001296
ParticipantsBG002
C-Reactive Protein (CRP)
Cohort 1 Analysis Population
Mean
Standard Deviation
mg/dL
Title
Denominators
Categories
ParticipantsBG000450
ParticipantsBG001301
ParticipantsBG002
DAS28-CRP
The Disease Activity Score (DAS28-CRP) =0.56×sqrt(tender joints [count:1-28])+0.28×sqrt(swollen joints [count:1-28])+0.36×Ln(CRP level+1)+0.014×(patient's disease assessment on 0-100 mm scale [100=most severe])+0.96. Range: 0.96 to no upper limit. Higher score=more severe disease.
Cohort 1 Analysis Population
Mean
Standard Deviation
Scores on a scale
Title
Denominators
Categories
ParticipantsBG000446
ParticipantsBG001298
ParticipantsBG002
SDAI
Simple Disease Activity Index is the numerical sum of five outcome parameters: tender joint count and swollen joint count based on a 28-joint assessment, patient global assessment and physician global assessment assessed on a visual analogue scale scale (range 0 to 10 cm), and C-reactive protein measured in mg/dL. SDAI total score range: 0 to 86. SDAI <= 3.3 indicates disease remission and SDAI >26 = high disease activity.
Cohort 1 Analysis Population
Mean
Standard Deviation
Scores on a scale
Title
Denominators
Categories
ParticipantsBG000443
ParticipantsBG001
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI <= 3.3.
Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI <= 3.3 indicates disease remission and SDAI >26 = high disease activity.
Primary analysis population included the first 50 Japanese and 325 rest of world (ROW) randomized and treated subjects in cohort 1 in the Induction Period. Intention to treat analysis. Non-Responder imputation.
Active abatacept SC (125 mg) weekly + methotrexate weekly
OG003
Abatacept + Methotrexate (De-Escalation Period)
Active Abatacept SC (125 mg) weekly + MTX weekly
OG004
Abatacept (End of Week) + Methotrexate (De-Escalation Period)
Active Abatacept SC (125 mg) alternating with placebo for abatacept every other week + MTX weekly
OG005
Abatacept Monotherapy (De-Escalation Period)
Active Abatacept SC (125 mg) weekly + placebo MTX weekly
OG006
Methotrexate Monotherapy (De-Escalation Period)
Placebo Abatacept SC weekly + methotrexate weekly
OG007
Abatacept + Methotrexate (Open Label Period)
weekly abatacept SC 125 mg + methotrexate
Units
Counts
Participants
OG000225
OG001150
OG0020
OG003
Title
Denominators
Categories
Title
Measurements
OG00021.3(16.0 to 26.7)
OG00116.0(10.1 to 21.9)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Regression, Logistic
0.2359
Superiority
Secondary
Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24
DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP <= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.
Primary analysis population included the first 50 Japanese and 325 rest of world (ROW) randomized and treated subjects in cohort 1 in the Induction Period. Intention to treat analysis. Non-Responder imputation.
Percentage of Participants in SDAI Remission at Week 52
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI <= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI <= 3.3 indicates disease remission and SDAI >26 = high disease activity.
Primary analysis population included the first 50 Japanese and 325 rest of world (ROW) randomized and treated subjects in cohort 1 in the Induction Period. Intention to treat analysis. Non-Responder imputation.
Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
OG001
Placebo + Methotrexate (Cohort 1, IP)
Placebo of Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
Secondary
Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52
The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.
Cohort 1 analysis population included all randomized and treated subjects in the Induction Period. Intention to treat analysis. Linear extrapolation imputation.
Percentage of Participants in Boolean Remission at Week 52
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.
Cohort 1 analysis population included all randomized and treated subjects in the Induction Period. Intention to treat analysis. Non-Responder imputation.
Active abatacept SC (125 mg) weekly + methotrexate weekly
OG003
Time Frame
approximately 54 months
Description
Participants from the Induction period (IP) cohorts randomized to the De-Escalation period. Participants from the induction period also entered the Open Label period. Participants from the De-Escalation period entered 1 of 2 the open label period or the open label extension period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Benign ovarian tumour
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Carcinoid tumour of the gastrointestinal tract
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Cervix carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Intraductal proliferative breast lesion
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Invasive ductal breast carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0011 affected301 at risk
EG0020 affected242 at risk
EG003
Metastases to lung
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Pancreatic carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Prostate cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Renal cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Squamous cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Squamous cell carcinoma of skin
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Superficial spreading melanoma stage unspecified
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Uterine leiomyoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Cerebrovascular accident
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Dysarthria
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Encephalopathy
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Epilepsy
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Hypoxic-ischaemic encephalopathy
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Lacunar infarction
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Lacunar stroke
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Seizure
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Subarachnoid haemorrhage
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Syncope
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Bipolar disorder
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Bladder prolapse
Renal and urinary disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Adenomyosis
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Benign prostatic hyperplasia
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Hydrometra
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Metrorrhagia
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Ovarian cyst
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Vaginal polyp
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Acute respiratory failure
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Bronchiectasis
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Pneumonia aspiration
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Pneumothorax
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Pulmonary congestion
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0021 affected242 at risk
EG003
Knee operation
Surgical and medical procedures
MedDRA 23.0
Systematic Assessment
EG0000 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Hypotension
Vascular disorders
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 23.0
Systematic Assessment
EG00012 affected451 at risk
EG00118 affected301 at risk
EG0024 affected242 at risk
EG0031 affected50 at risk
EG0041 affected50 at risk
EG0050 affected47 at risk
EG0061 affected37 at risk
EG00710 affected685 at risk
EG0081 affected120 at risk
Abdominal pain upper
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG00012 affected451 at risk
EG0015 affected301 at risk
EG00214 affected242 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG00017 affected451 at risk
EG00112 affected301 at risk
EG00213 affected242 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG00042 affected451 at risk
EG00124 affected301 at risk
EG00222 affected242 at risk
EG003
Stomatitis
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG00027 affected451 at risk
EG0018 affected301 at risk
EG0021 affected242 at risk
EG003
Drug intolerance
General disorders
MedDRA 23.0
Systematic Assessment
EG0007 affected451 at risk
EG0014 affected301 at risk
EG0020 affected242 at risk
EG003
Bronchitis
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00019 affected451 at risk
EG00112 affected301 at risk
EG00216 affected242 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00013 affected451 at risk
EG0019 affected301 at risk
EG00210 affected242 at risk
EG003
Herpes zoster
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG0003 affected451 at risk
EG0012 affected301 at risk
EG0021 affected242 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00063 affected451 at risk
EG00143 affected301 at risk
EG00236 affected242 at risk
EG003
Pharyngitis
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00022 affected451 at risk
EG00117 affected301 at risk
EG00214 affected242 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00024 affected451 at risk
EG00116 affected301 at risk
EG00218 affected242 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG00017 affected451 at risk
EG0019 affected301 at risk
EG00213 affected242 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA 23.0
Systematic Assessment
EG00024 affected451 at risk
EG00115 affected301 at risk
EG00210 affected242 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA 23.0
Systematic Assessment
EG00014 affected451 at risk
EG00110 affected301 at risk
EG0029 affected242 at risk
EG003
Influenza A virus test positive
Investigations
MedDRA 23.0
Systematic Assessment
EG0001 affected451 at risk
EG0010 affected301 at risk
EG0020 affected242 at risk
EG003
Headache
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG00031 affected451 at risk
EG00121 affected301 at risk
EG0028 affected242 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG00015 affected451 at risk
EG00116 affected301 at risk
EG00213 affected242 at risk
EG003
Hypertension
Vascular disorders
MedDRA 23.0
Systematic Assessment
EG00011 affected451 at risk
EG0018 affected301 at risk
EG0025 affected242 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.